{"url_path":"/sec/rlay/8-k/2026-04-27/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-179404-index.html","accession_number":"0001193125-26-179404","cik":"0001812364","ticker":"RLAY","issuer_name":"Relay Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-179404-index.html","primary_entity_key":"0001812364","primary_entity_name":"Relay Therapeutics, Inc."},"word_count":236,"has_tables":true,"body_markdown":"## Item 7.01 Regulation FD Disclosure.\n\nOn April 27, 2026, Relay Therapeutics, Inc. (the \"Company\") issued a press release announcing clinical data from the zovegalisib, fulvestrant and atirmociclib triplet combination arm of the Phase 1/2 ReDiscover trial as well as the Company's plans to move zovegalisib plus atirmociclib into Phase 3 development for frontline (\"1L\") patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The Company hosted a conference call and live webcast to discuss the clinical data and Phase 3 development plans on April 27, 2026 at 8:30 a.m. E.T. The Company has made available a slide presentation to accompany the call, a copy of which is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.\n\n \n\nThe information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}